PTC Therapeutics Inc (PTCT : NASDAQ)
Common Stock
$65.95
USD
+3.28 (5.23%)
Last updated: 2026-09-28
Follow PTCT
PTCT
PTC Therapeutics Inc
WealthAwesomePerformance
1 Day
+5.23%
1 Week
+1.06%
1 Month
-5.91%
YTD
-16.02%
Key Statistics
Market Cap
$5.50B
52W High
$90.87
52W Low
$60.80
P/E Ratio
-
50 Day MA
$70.66
200 Day MA
$72.38
Beta
0.55
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/28/2026 | $62.35 | $66.26 | $62.30 | $65.95 | $65.95 | 1,913,632 |
| 9/25/2026 | $62.65 | $63.44 | $61.66 | $62.67 | $62.67 | 1,203,000 |
| 9/24/2026 | $62.23 | $62.76 | $61.23 | $62.28 | $62.28 | 1,754,258 |
| 9/23/2026 | $65.80 | $66.15 | $62.24 | $62.34 | $62.34 | 1,101,125 |
| 9/22/2026 | $66.24 | $66.58 | $65.36 | $65.96 | $65.96 | 1,307,186 |
| 9/21/2026 | $65.93 | $66.21 | $64.99 | $65.26 | $65.26 | 1,043,702 |
| 9/18/2026 | $68.00 | $68.00 | $65.18 | $65.37 | $65.37 | 3,865,000 |
| 9/17/2026 | $68.84 | $68.84 | $67.22 | $68.00 | $68.00 | 1,090,412 |
| 9/16/2026 | $65.99 | $67.90 | $65.80 | $67.59 | $67.59 | 1,397,895 |
| 9/15/2026 | $66.51 | $66.54 | $65.06 | $65.65 | $65.65 | 1,034,204 |
Analyst Price Targets
Based on 14 analysts covering PTCT · as of Sep 23, 2026
Wall Street analysts forecast PTCT stock price to rise 54.3% over the next 12 months.
Consensus
Buy3.86 / 5.00
Avg. Target
US$101.79
+54.3% Upside
Previously US$101.29 on Sep 17, 2026
Current Price
US$65.95
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PTCT's historical volatility
30-Day Vol
36.6%
Annualized
90-Day Vol
39.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$55.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$62.14 | US$54.77 – US$70.49 |
| 60 trading days | US$58.55 | US$48.98 – US$69.98 |
| 90 trading days | US$55.16 | US$44.34 – US$68.64 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Financials
- Revenue (TTM)
- $1.01B
- EBITDA
- $171.22M
- Profit Margin
- -3.81%
- ROE (TTM)
- -7740.12%
- EPS (Diluted)
- -0.67
- Book Value
- -1.99
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About PTCT.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DCX | Digital Currency X Technology Inc. | $6.17 | +12491.84% |
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.44 | +12100.00% |
| CTNT | Cheetah Net Supply Chain Service Inc. Class A Common Stock | $3.60 | +11150.00% |
| GMEX | GMEX ROBOTICS CORPORATION | $3.24 | +7880.30% |
| IFRX | InflaRx N.V. | $150.00 | +7836.51% |
| FBGL | FBS Global Limited Ordinary Shares | $4.30 | +1019.79% |
| KOD | Kodiak Sciences Inc | $89.92 | +177.96% |
| LFCR | Lifecore Biomedical Inc. | $6.52 | +55.24% |
PTCT.US news timeline
1 article covering PTCT.US, most recent first
Latest